etravirine has been researched along with delavirdine mesylate in 9 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (delavirdine mesylate) | Trials (delavirdine mesylate) | Recent Studies (post-2010) (delavirdine mesylate) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 17 | 0 | 9 |
| Protein | Taxonomy | etravirine (IC50) | delavirdine mesylate (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.99 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.8924 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doak, AK; Prusiner, SB; Shoichet, BK; Wille, H | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Chen, X; Cheng, Z; De Clercq, E; Liu, X; Meng, C; Pannecouque, C; Shao, S; Zhan, P | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
| Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
| Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
| De Clercq, E; Huo, Z; Kang, D; Liu, H; Liu, X; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H; Zhou, Z | 1 |
9 other study(ies) available for etravirine and delavirdine mesylate
| Article | Year |
|---|---|
Colloid formation by drugs in simulated intestinal fluid.
Topics: Buffers; Chemical Precipitation; Colloids; Intestine, Small; Light; Microscopy, Electron, Transmission; Pharmaceutical Preparations; Scattering, Radiation; Solubility | 2010 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line; Chemistry Techniques, Synthetic; HIV Reverse Transcriptase; HIV-1; Inhibitory Concentration 50; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
Topics: Amines; Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Piperidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2012 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Mice; Models, Molecular; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Uracil | 2017 |